Golimumab News and Research

RSS

Charting the future of IBD treatment: From immune modulators to microRNA therapies

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.

8 Nov 2023

Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract.

7 Nov 2023

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Researchers compared changes in inflammatory bowel disease treatment strategies before and after the introduction of biologics in Japan.

24 Aug 2023

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients.

8 Nov 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Anti-TNF drug preserves beta-cell function in newly diagnosed pediatric patients with Type 1 diabetes

In research led by a University at Buffalo pediatric endocrinologist, a drug called golimumab showed that it preserved beta-cell function in children and young adults with newly diagnosed Type 1 diabetes, according to findings from a Phase 2 study.

16 Jun 2020

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

5 Jun 2020

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

New therapeutic target for rheumatoid arthritis and type 2 diabetes

There is a growing body of knowledge that points that type 2 diabetes, a chronic disease where the blood sugar increases, is an inflammatory disease. The levels of certain inflammatory chemicals, dubbed as cytokines, are often higher in people with type 2 diabetes, than healthy people.

16 Sep 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA).

13 Jun 2016

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

16 Dec 2014

Golimumab News and Research

Charting the future of IBD treatment: From immune modulators to microRNA therapies

Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Anti-TNF drug preserves beta-cell function in newly diagnosed pediatric patients with Type 1 diabetes

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

New therapeutic target for rheumatoid arthritis and type 2 diabetes

Toxic effects of drugs in the lungs 'more widespread than thought'

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News